© 2020 MJH Life Sciences, Dermatology Times and Multimedia Medical, LLC. All rights reserved.
Psoriasis
FDA approves ustekinumab for pediatric psoriasis
August 07, 2020
The U.S. Food and Drug Administration has approved IL-12/IL-23 inhibitor ustekinumab (Stelara, Janssen Pharmaceutical Companies of Johnson & Johnson) for treatment of moderate-to-severe plaque psoriasis in pediatric patients 6-11 years.
The Cutaneous Connection: Episode 4- Probiotics for Psoriasis?
August 06, 2020
This episode dives into emerging research regarding probiotics specifically tailored to treat psoriasis and possibly other inflammatory skin diseases.
EC approves secukinumab for pediatric psoriasis
August 04, 2020
The European Commission has approved secukinumab (Cosentyx, Novartis) for treatment of moderate-to-severe plaque psoriasis in pediatric patients 6